Free Trial
NASDAQ:AFMD

Affimed (AFMD) Stock Price, News & Analysis

$5.15
-0.01 (-0.19%)
(As of 05/21/2024 ET)
Today's Range
$4.73
$5.24
50-Day Range
$4.40
$6.66
52-Week Range
$2.23
$11.10
Volume
69,060 shs
Average Volume
87,135 shs
Market Capitalization
$78.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.00

Affimed MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
773.8% Upside
$45.00 Price Target
Short Interest
Healthy
1.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.70mentions of Affimed in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.96) to ($2.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.21 out of 5 stars

Medical Sector

142nd out of 921 stocks

Pharmaceutical Preparations Industry

56th out of 416 stocks

AFMD stock logo

About Affimed Stock (NASDAQ:AFMD)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

AFMD Stock Price History

AFMD Stock News Headlines

Affimed (NASDAQ:AFMD) Short Interest Update
Q4 2023 Affimed NV Earnings Call Transcript
Here's what Wall Street expects from Affimed's earnings
A Preview Of Affimed's Earnings
Why Is Affimed (AFMD) Stock Moving Today?
Affimed Announces 1-for-10 Reverse Stock Split
See More Headlines
Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
5/21/2024
Next Earnings (Estimated)
5/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AFMD
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$45.00
High Stock Price Target
$70.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+796.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-114,660,000.00
Net Margins
-1,280.27%
Pretax Margin
-1,280.19%

Debt

Sales & Book Value

Annual Sales
$8.95 million
Book Value
$4.19 per share

Miscellaneous

Free Float
14,648,000
Market Cap
$76.45 million
Optionable
Optionable
Beta
2.05
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Andreas Harstrick M.D. (Age 63)
    Interim CEO, Chief Medical Officer & Member of Management Board
    Comp: $535.09k
  • Dr. Wolfgang Fischer (Age 60)
    MD, COO & Member of Management Board
    Comp: $645.58k
  • Ms. Denise Mueller (Age 54)
    Chief Business Officer & Member of Management Board
    Comp: $628.24k
  • Prof. Melvyn Little
    Founder & Consultant
  • Mr. Michael Wolf (Age 57)
    Head of Finance & Administration
  • Mr. Alexander Fudukidis
    Head of Investor Relations & Director of Investor Relations
  • Mary Beth Sandin
    Vice President of Marketing & Communications

AFMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Affimed stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AFMD shares.
View AFMD analyst ratings
or view top-rated stocks.

What is Affimed's stock price target for 2024?

5 Wall Street analysts have issued 12-month price targets for Affimed's shares. Their AFMD share price targets range from $10.00 to $70.00. On average, they expect the company's share price to reach $45.00 in the next year. This suggests a possible upside of 773.8% from the stock's current price.
View analysts price targets for AFMD
or view top-rated stocks among Wall Street analysts.

How have AFMD shares performed in 2024?

Affimed's stock was trading at $6.25 at the beginning of 2024. Since then, AFMD stock has decreased by 17.6% and is now trading at $5.15.
View the best growth stocks for 2024 here
.

When is Affimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024.
View our AFMD earnings forecast
.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) announced its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($1.30) by $0.10. The biopharmaceutical company earned $10.21 million during the quarter, compared to analysts' expectations of $11.79 million. Affimed had a negative net margin of 1,280.27% and a negative trailing twelve-month return on equity of 118.17%. During the same period last year, the business earned ($0.80) earnings per share.

When did Affimed's stock split?

Affimed's stock reverse split before market open on Monday, March 11th 2024. The 1-10 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Affimed own?
Who are Affimed's major shareholders?

Affimed's stock is owned by a number of retail and institutional investors. Top institutional investors include NEA Management Company LLC (2.91%), BNP Paribas Financial Markets (0.48%), Nan Fung Group Holdings Ltd (0.24%), Kennedy Capital Management LLC (0.07%), Harbor Investment Advisory LLC (0.04%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Affimed?

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AFMD) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners